Cardlytics, Inc. (NASDAQ:CDLX) Expected to Post Earnings of -$0.50 Per Share

Equities research analysts expect that Cardlytics, Inc. (NASDAQ:CDLX) will announce earnings of ($0.50) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cardlytics’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.58). Cardlytics posted earnings per share of ($0.16) during the same quarter last year, which suggests a negative year-over-year growth rate of 212.5%. The business is expected to announce its next quarterly earnings results on Monday, November 1st.

According to Zacks, analysts expect that Cardlytics will report full-year earnings of ($1.50) per share for the current year, with EPS estimates ranging from ($1.69) to ($1.30). For the next year, analysts forecast that the company will report earnings of ($1.20) per share, with EPS estimates ranging from ($1.41) to ($0.98). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Cardlytics.

Cardlytics (NASDAQ:CDLX) last announced its earnings results on Tuesday, August 3rd. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.19). Cardlytics had a negative net margin of 41.88% and a negative return on equity of 15.50%. The business had revenue of $58.85 million for the quarter, compared to the consensus estimate of $63.23 million.

Several brokerages recently weighed in on CDLX. Craig Hallum decreased their target price on Cardlytics from $160.00 to $120.00 and set a “buy” rating for the company in a research note on Wednesday, August 4th. Zacks Investment Research increased their target price on Cardlytics to $105.00 in a research note on Monday, August 30th. TheStreet downgraded Cardlytics from a “c-” rating to a “d+” rating in a research report on Wednesday, August 4th. Finally, Needham & Company LLC reduced their price objective on Cardlytics from $135.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday, August 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cardlytics has an average rating of “Hold” and an average price target of $129.00.

Shares of NASDAQ:CDLX opened at $96.45 on Wednesday. The business has a 50 day moving average price of $98.22 and a 200 day moving average price of $109.77. Cardlytics has a twelve month low of $64.20 and a twelve month high of $161.47. The company has a market cap of $3.19 billion, a price-to-earnings ratio of -31.31 and a beta of 2.54. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35.

In related news, CFO Andrew Christiansen sold 750 shares of the firm’s stock in a transaction on Monday, July 12th. The stock was sold at an average price of $122.30, for a total transaction of $91,725.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director S Aimee Lapic sold 3,176 shares of the firm’s stock in a transaction on Monday, June 28th. The shares were sold at an average price of $127.32, for a total value of $404,368.32. Following the sale, the director now directly owns 6,198 shares of the company’s stock, valued at $789,129.36. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 372,619 shares of company stock valued at $32,438,256 and have sold 27,802 shares valued at $2,990,041. 6.50% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP increased its stake in shares of Cardlytics by 53.8% in the 2nd quarter. Marshall Wace LLP now owns 125,630 shares of the company’s stock valued at $15,946,000 after buying an additional 43,950 shares during the period. Jefferies Group LLC acquired a new stake in shares of Cardlytics in the 2nd quarter valued at $18,016,000. Worth Venture Partners LLC increased its stake in shares of Cardlytics by 71.6% in the 2nd quarter. Worth Venture Partners LLC now owns 24,245 shares of the company’s stock valued at $3,077,000 after buying an additional 10,115 shares during the period. Capital Impact Advisors LLC acquired a new stake in shares of Cardlytics in the 2nd quarter valued at $1,041,000. Finally, Metropolitan Life Insurance Co NY increased its stake in shares of Cardlytics by 105,737.5% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 8,467 shares of the company’s stock valued at $1,075,000 after buying an additional 8,459 shares during the period. 94.51% of the stock is owned by hedge funds and other institutional investors.

About Cardlytics

Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.

Featured Article: What factors cause inflation to rise?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.